WESTBOROUGH, Mass.–(BUSINESS WIRE)–BJ’s Wholesale Club (NYSE: BJ), a leading operator of membership warehouse clubs in the Eastern United States, today announced a new online shopping experience for BJ’s Optical, which allows shoppers to purchase sun…
Author: Business Wire
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Kubota Vision to Present at the Ophthalmology Innovation Summit (OIS) Myopia Innovation Showcase
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that Ryo Kubota, MD, PhD, Chairman, Pre…
Eye Health America Continues Expanding Across the Southeast Partnering With the Eye Care Center in Upstate South Carolina
GREENVILLE, S.C.–(BUSINESS WIRE)–Today, Eye Health America (EHA), a leading eye care practice management organization in the Southeast, welcomes Drs. William Milford and Marion K. Williams of The Eye Care Center, into its business family. The Eye Car…
Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)– #ARVO2021–Allegro Ophthalmics will present four scientific posters on risuteganib, its lead investigational compound in retina, during the 2021 ARVO Meeting.
Biomarck’s MARCKS Inhibitors for Uveitis to be Presented at the 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
NEWTOWN, Pa.–(BUSINESS WIRE)– #cytokinestorm–Biomarck’s MARCKS inhibitors for uveitis will be presented at the 2021 Annual Meeting of Association for Research in Vision and Ophthalmology (ARVO).
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Glaukos Announces the Release of its 2020 Sustainability Report
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
CHMP empfiehlt EU-Zulassung von Enspryng (Satralizumab) von Chugai für Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) hat heute bekannt gegeben, dass Roche eine Mitteilung vom Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) erhalten hat, wonach dieser die Zulassung…
CHMP recommande l'approbation par l'UE de l'Enspryng (satralizumab) de Chugai pour le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé aujourd’hui que, selon une notification adressée à la société Roche, le comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments (EMA) a recomma…
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M….
Midwest Vision Partners Announces Partnership With Eye Centers of Ohio
CHICAGO & CANTON, OHIO–(BUSINESS WIRE)– #eyecare–Midwest Vision Partners Announces Partnership With Eye Centers of Ohio
Resumen: El CHMP recomienda la aprobación en la UE de Enspryng (satralizumab) de Chugai para el trastorno del espectro de la neuromielitis óptica (TENMO)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado hoy que Roche ha recibido la notificación de que el Comité de Medicamentos de Uso Humano (CHMP en sus siglas en inglés) de la Agencia Europea del Medicamento (EMA) ha re…
CHMP 建議歐盟核准將中外製藥的Enspryng (Satralizumab)用於治療泛視神經脊髓炎(NMOSD)
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO:4519)今天宣布，羅氏(Roche)已收到通知指出，歐洲藥品管理局(EMA)人用藥品委員會(CHMP)建議核准中外製藥研製的pH依賴型結合人源化抗IL-6受體單株抗體Enspryng® (satralizumab)，將其作為抗水通道蛋白-4抗體(AQP4-IgG)血清陽性的成人及12歲以上青少年泛視神經脊髓炎(NMOSD)患者的首個皮下治療選…
Samenvatting: CHMP beveelt EU-goedkeuring aan van Chugai’s Enspryng (Satralizumab) voor Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft vandaag aangekondigd dat Roche een kennisgeving heeft ontvangen dat het Committee for Medicinal Products for Human Use (CHMP) van het European Medicines Agency’s (EMA) de goedk…
Riassunto: Il CHMP raccomanda l’approvazione da parte della UE di Enspryng (satralizumab) di Chugai per il disturbo dello spettro della neuromielite ottica (Neuromyelitis Optica Spectrum Disorder, NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha annunciato oggi che Roche ha ricevuto la notifica che il Comitato per i medicinali per uso umano (Committee for Medicinal Products for Human Use, CHMP) dell’Agenzia europea per i m…
CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of t…
Bollé Safety biedt nu Trivex-lenzen voor haar veiligheidsbrillen op sterkte
VILLEURBANNE, Frankrijk–(BUSINESS WIRE)–Wereldwijde oogbeschermingsspecialist Bollé Safety biedt nu Trivex aan. Een hoogwaardige, hoogtechnologische lens op sterkte die maximale veiligheid en uitstekende optische eigenschappen biedt om de beste veili…
jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting